AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY

Trial Profile

AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Kidney disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 05 Aug 2015 Planned End Date changed from 31 Dec 2013 to 31 May 2014 as reported by University Hospital Medical Information Network - Japan.
    • 05 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top